DOCSLIB.ORG

Novel Properties of Hnrnp-Ul1: Its Possible Role in the Pathogenesis of Als

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Novel Properties of Hnrnp-Ul1: Its Possible Role in the Pathogenesis of Als NOVEL PROPERTIES OF HNRNP-UL1: ITS POSSIBLE ROLE IN THE PATHOGENESIS OF ALS. By KENNY MATTHEW PRATT A thesis submitted to the University of Birmingham for the degree of DOCTOR OF PHILOSOPHY Institute of Cancer and Genomic Sciences The Medical School University of Birmingham October 2015 University of Birmingham Research Archive e-theses repository This unpublished thesis/dissertation is copyright of the author and/or third parties. The intellectual property rights of the author or third parties in respect of this work are as defined by The Copyright Designs and Patents Act 1988 or as modified by any successor legislation. Any use made of information contained in this thesis/dissertation must be in accordance with that legislation and must be properly acknowledged. Further distribution or reproduction in any format is prohibited without the permission of the copyright holder. ABSTRACT Heterogeneous nuclear ribonucleoprotein-U like 1 (hnRNP-UL1) is a protein with numerous roles within the cell, including RNA processing and responses to DNA damage. Within this study two novel aspects of the protein are explored: the role of a putative nucleotide-binding domain and the protein’s possible involvement in amyotrophic lateral sclerosis (ALS). hnRNP-UL1 is known to have a putative nucleotide-binding domain within its central region containing both a Walker A and Walker B motif. This region had not been investigated previously and was therefore of great interest in this study. The Walker A motif was shown to bind adenosine triphosphate (ATP) and the region appears to possess protein kinase activity. A biological substrate and function for these activities were not established, but these observations suggest that there are still layers of complexity to hnRNP-UL1’s cellular roles to be elucidated. ALS is a late-onset neurodegenerative disease with limited treatment strategies and poor patient outcomes. Many of the proteins involved in its pathogenesis have two properties in common: they have roles in RNA-processing and possess prion-like domains (PrLDs). The properties of hnRNP-UL1 appertain to both of these and therefore it was of great interest when ALS patients were discovered with heterozygous hnRNP-UL1 mutations. Results showed that cells possessing the ALS patient mutations (R639C and R468C) had no DNA damage response (DDR) defects or mislocalisation of the protein, but their ssDNA/RNA- binding capability was markedly reduced. Whilst no direct causative links to ALS pathogenesis were shown with the hnRNP-UL1 patient mutations in this study, growing evidence implies good reason for the protein to have involvement in the disease. ACKNOWLEDGEMENTS I am extremely grateful to my supervisor, Roger, for his continued help and advice in all aspects of the work I have undertaken as part of my PhD. He is responsible for me coming to Birmingham to pursue working in science and I am very glad to have completed my research under his experienced and nurturing tutorage. There are also many other members of staff that I would like to thank for their help and friendship. Andy provided good advice and guidance on the project, as well as daily sport-related chats. I am also thankful to Grant for his advice and knowledge, plus reagents and equipment. I must thank Elizabeth, Sally, Ruth, Helen, Kirsty, Alex, Tom, John, Martin, Phil and Rob for help along the way, and particularly Ruth and Elizabeth for technical help with certain procedures. I also thank the whole IBR 1st floor who are a great bunch of people and it is a welcoming and friendly place to work. I am also thankful for the financial support given to me by the University of Birmingham Medical School and the Medical Research Council. Finally, I would like to thank every single member of my family for supporting me from when I was young right up until this point, especially my Ma and Pa. I started my own family whilst doing this PhD and nothing has kept me happier during this time in my life than my wife Hannah and son Henry. Coming home to play with Henry helped to relieve stress and put in to perspective a failed experiment. Finally, thank you Hannah for all the love, commitment and sacrifices made in the past four years. TABLE OF CONTENTS I INTRODUCTION ........................................................................................................... 1 1.1 The DNA molecule ...................................................................................................... 2 1.2 The DNA damage response (DDR).............................................................................. 4 1.2.1 Single strand break (SSB) repair ......................................................................... 8 1.2.2 Base excision repair (BER) ............................................................................... 10 1.2.3 Nucleotide excision repair (NER) ..................................................................... 11 1.2.4 Non-homologous end joining (NHEJ) .............................................................. 11 1.2.5 Homologous recombination (HR)..................................................................... 13 1.2.6 Diseases associated with malfunction of the DDR ........................................... 16 1.3 Heteronuclear ribonucleoproteins (hnRNPs) ............................................................. 24 1.3.1 hnRNPs ............................................................................................................. 24 1.3.2 hnRNP-UL1 ...................................................................................................... 26 1.3.3 hnRNPs in the DDR .......................................................................................... 30 1.3.4 hnRNP-UL1 in the DDR ................................................................................... 33 1.3.5 hnRNP-UL1’s Walker A motif and activity of PNKP...................................... 36 1.4 Amyotrophic lateral sclerosis (ALS) .......................................................................... 42 1.4.1 ALS aetiology and pathogenesis ....................................................................... 43 1.4.2 RNA processing and ALS ................................................................................. 49 1.4.3 Prion-like domain (PrLD) proteins and ALS .................................................... 53 1.4.4 ALS and the DDR ............................................................................................. 57 1.5 Aims ........................................................................................................................... 62 II MATERIALS AND METHODS ................................................................................. 63 2.1 Cell biology techniques .............................................................................................. 64 2.1.1 Cell lines ........................................................................................................... 64 2.1.2 Cell culture media ............................................................................................. 64 2.1.3 Maintenance and passage of cell lines .............................................................. 64 2.1.4 Cryopreservation of cell lines ........................................................................... 65 2.1.5 IR and UV irradiation ....................................................................................... 65 2.1.6 Drug treatments ................................................................................................. 66 2.1.6.1 Camptothecin ............................................................................................... 66 2.1.6.2 Kinase inhibitors .......................................................................................... 66 2.1.6.3 Tert-butylhydroquinone ............................................................................... 67 2.1.7 RNA interference (RNAi) ................................................................................. 67 2.1.8 Transfection of plasmid DNA ........................................................................... 68 2.2 Molecular biology techniques .................................................................................... 69 2.2.1 Preparation of media and plates ........................................................................ 69 2.2.2 Bacterial transformations .................................................................................. 69 2.2.3 Large scale preparation of DNA plasmids ........................................................ 70 2.2.4 Agarose gel electrophoresis .............................................................................. 71 2.2.5 Site-directed mutagenesis PCR ......................................................................... 72 2.2.6 DNA sequencing ............................................................................................... 73 2.2.7 Cloning .............................................................................................................. 74 2.3 Protein and DNA biochemistry techniques ................................................................ 75 2.3.1 Preparation of total cell lysates ......................................................................... 75 2.3.2 Preparation of lysates from cells for co-immunoprecipitation ......................... 76 2.3.3 Determination of protein concentration ............................................................ 76 2.3.4 SDS-polyacrylamide gel
Load more

Recommended publications
  • The Role of Arginine Methylation of Hnrnpul1 in the DNA Damage Response Pathway Gayathri Gurunathan
    The role of arginine methylation of hnRNPUL1 in the DNA damage response pathway Gayathri Gurunathan Faculty of Medicine Division of Experimental Medicine McGill University, Montreal, Quebec, Canada August 2014 A Thesis Submitted to McGill University in Partial Fulfillment of the Requirements for the Degree of Master of Science © Gayathri Gurunathan 2014 Abstract Post-translational modifications play a key role in mediating the DNA damage response (DDR). It is well-known that serine/threonine phosphorylation is a major post-translational modification required for the amplification of the DDR; however, less is known about the role of other modifications, such as arginine methylation. It is known that arginine methylation of the DDR protein, MRE11, by protein arginine methyltransferase 1 (PRMT1) is essential for the response, as the absence of methylation of MRE11 in mice leads to hypersensitivity to DNA damage agents. Herein, we identify hnRNPUL1 as a substrate of PRMT1 and the methylation of hnRNPUL1 is required for DNA damage signalling. I show that several RGG/RG sequences of hnRNPUL1 are methylated in vitro by PRMT1. Recombinant glutathione S-transferase (GST) proteins harboring hnRNPUL1 RGRGRG, RGGRGG and a single RGG were efficient in vitro substrates of PRMT1. Moreover, I performed mass spectrometry analysis of Flag-hnRNPUL1 and identified the same sites methylated in vivo. PRMT1-depletion using RNA interference led to the hypomethylation of hnRNPUL1, consistent with PRMT1 being the only enzyme in vivo to methylate these sequences. We replaced the arginines with lysine in hnRNPUL1 (Flag- hnRNPUL1RK) such that this mutant protein cannot be methylated by PRMT1. Indeed Flag- hnRNPUL1RK was undetected using specific dimethylarginine antibodies.
    [Show full text]
  • Genetic and Pharmacological Approaches to Preventing Neurodegeneration
    University of Pennsylvania ScholarlyCommons Publicly Accessible Penn Dissertations 2012 Genetic and Pharmacological Approaches to Preventing Neurodegeneration Marco Boccitto University of Pennsylvania, [email protected] Follow this and additional works at: https://repository.upenn.edu/edissertations Part of the Neuroscience and Neurobiology Commons Recommended Citation Boccitto, Marco, "Genetic and Pharmacological Approaches to Preventing Neurodegeneration" (2012). Publicly Accessible Penn Dissertations. 494. https://repository.upenn.edu/edissertations/494 This paper is posted at ScholarlyCommons. https://repository.upenn.edu/edissertations/494 For more information, please contact [email protected]. Genetic and Pharmacological Approaches to Preventing Neurodegeneration Abstract The Insulin/Insulin-like Growth Factor 1 Signaling (IIS) pathway was first identified as a major modifier of aging in C.elegans. It has since become clear that the ability of this pathway to modify aging is phylogenetically conserved. Aging is a major risk factor for a variety of neurodegenerative diseases including the motor neuron disease, Amyotrophic Lateral Sclerosis (ALS). This raises the possibility that the IIS pathway might have therapeutic potential to modify the disease progression of ALS. In a C. elegans model of ALS we found that decreased IIS had a beneficial effect on ALS pathology in this model. This beneficial effect was dependent on activation of the transcription factor daf-16. To further validate IIS as a potential therapeutic target for treatment of ALS, manipulations of IIS in mammalian cells were investigated for neuroprotective activity. Genetic manipulations that increase the activity of the mammalian ortholog of daf-16, FOXO3, were found to be neuroprotective in a series of in vitro models of ALS toxicity.
    [Show full text]
  • ATP Is Required for Interactions Between UAP56 and Two Conserved Mrna Export Proteins, Aly and CIP29, to Assemble the TREX Complex
    ATP is required for interactions between UAP56 and two conserved mRNA export proteins, Aly and CIP29, to assemble the TREX complex Kobina Dufu,1 Michaela J. Livingstone,2 Jan Seebacher,1 Steven P. Gygi,1 Stuart A. Wilson,2 and Robin Reed1,3 1Department of Cell Biology, Harvard Medical School, Boston, Massachusetts 02115, USA; 2Department of Molecular Biology and Biotechnology, University of Sheffield, Western Bank, Sheffield S10 2TN, United Kingdom The conserved TREX mRNA export complex is known to contain UAP56, Aly, Tex1, and the THO complex. Here, we carried out proteomic analysis of immunopurified human TREX complex and identified the protein CIP29 as the only new component with a clear yeast relative (known as Tho1). Tho1 is known to function in mRNA export, and we provide evidence that CIP29 likewise functions in this process. Like the known TREX components, a portion of CIP29 localizes in nuclear speckle domains, and its efficient recruitment to mRNA is both splicing- and cap-dependent. We show that UAP56 mediates an ATP-dependent interaction between the THO complex and both CIP29 and Aly, indicating that TREX assembly is ATP-dependent. Using recombinant proteins expressed in Escherichia coli, we show that UAP56, Aly, and CIP29 form an ATP-dependent trimeric complex, and UAP56 bridges the interaction between CIP29 and Aly. We conclude that the interaction of two conserved export proteins, CIP29 and Aly, with UAP56 is strictly regulated by ATP during assembly of the TREX complex. [Keywords: CIP29; Aly; UAP56; TREX complex; Tho1; helicase] Supplemental material is available at http://www.genesdev.org. Received December 20, 2009; revised version accepted July 30, 2010.
    [Show full text]
  • HNRPUL1 (HNRNPUL1) Rabbit Polyclonal Antibody Product Data
    OriGene Technologies, Inc. 9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 [email protected] EU: [email protected] CN: [email protected] Product datasheet for TA345996 HNRPUL1 (HNRNPUL1) Rabbit Polyclonal Antibody Product data: Product Type: Primary Antibodies Applications: IF, IHC, IP, WB Recommended Dilution: IF, IP, WB, IHC Reactivity: Human Host: Rabbit Isotype: IgG Clonality: Polyclonal Immunogen: The immunogen for anti-HNRPUL1 antibody: synthetic peptide directed towards the C terminal of human HNRPUL1. Synthetic peptide located within the following region: TYPQPSYNQYQQYAQQWNQYYQNQGQWPPYYGNYDYGSYSGNTQGGTSTQ Formulation: Liquid. Purified antibody supplied in 1x PBS buffer with 0.09% (w/v) sodium azide and 2% sucrose. Note that this product is shipped as lyophilized powder to China customers. Purification: Protein A purified Conjugation: Unconjugated Storage: Store at -20°C as received. Stability: Stable for 12 months from date of receipt. Predicted Protein Size: 83 kDa Gene Name: heterogeneous nuclear ribonucleoprotein U like 1 Database Link: NP_653333 Entrez Gene 11100 Human Q9BUJ2 This product is to be used for laboratory only. Not for diagnostic or therapeutic use. View online » ©2021 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US 1 / 4 HNRPUL1 (HNRNPUL1) Rabbit Polyclonal Antibody – TA345996 Background: HNRPUL1 is a nuclear RNA-binding protein of the heterogeneous nuclear ribonucleoprotein (hnRNP) family. This protein binds specifically to adenovirus E1B-55kDa oncoprotein. It may play an important role in nucleocytoplasmic RNA transport, and its function is modulated by E1B-55kDa in adenovirus-infected cells.This gene encodes a nuclear RNA-binding protein of the heterogeneous nuclear ribonucleoprotein (hnRNP) family.
    [Show full text]
  • HNRPUL1 (HNRNPUL1) (NM 007040) Human Tagged ORF Clone Product Data
    OriGene Technologies, Inc. 9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 [email protected] EU: [email protected] CN: [email protected] Product datasheet for RC200576L3 HNRPUL1 (HNRNPUL1) (NM_007040) Human Tagged ORF Clone Product data: Product Type: Expression Plasmids Product Name: HNRPUL1 (HNRNPUL1) (NM_007040) Human Tagged ORF Clone Tag: Myc-DDK Symbol: HNRNPUL1 Synonyms: E1B-AP5; E1BAP5; HNRPUL1 Vector: pLenti-C-Myc-DDK-P2A-Puro (PS100092) E. coli Selection: Chloramphenicol (34 ug/mL) Cell Selection: Puromycin ORF Nucleotide The ORF insert of this clone is exactly the same as(RC200576). Sequence: Restriction Sites: SgfI-MluI Cloning Scheme: ACCN: NM_007040 ORF Size: 2568 bp This product is to be used for laboratory only. Not for diagnostic or therapeutic use. View online » ©2021 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US 1 / 2 HNRPUL1 (HNRNPUL1) (NM_007040) Human Tagged ORF Clone – RC200576L3 OTI Disclaimer: The molecular sequence of this clone aligns with the gene accession number as a point of reference only. However, individual transcript sequences of the same gene can differ through naturally occurring variations (e.g. polymorphisms), each with its own valid existence. This clone is substantially in agreement with the reference, but a complete review of all prevailing variants is recommended prior to use. More info OTI Annotation: This clone was engineered to express the complete ORF with an expression tag. Expression varies depending on the nature of the gene. RefSeq: NM_007040.2 RefSeq Size: 3892 bp RefSeq ORF: 2571 bp Locus ID: 11100 UniProt ID: Q9BUJ2 Domains: SAP, SPRY Protein Families: Druggable Genome MW: 95.8 kDa Gene Summary: This gene encodes a nuclear RNA-binding protein of the heterogeneous nuclear ribonucleoprotein (hnRNP) family.
    [Show full text]
  • DNA Damage Triggers SAF-A and RNA Biogenesis
    Published online 16 July 2014 Nucleic Acids Research, 2014, Vol. 42, No. 14 9047–9062 doi: 10.1093/nar/gku601 DNA damage triggers SAF-A and RNA biogenesis factors exclusion from chromatin coupled to R-loops removal Sebastien´ Britton1,2,3,†, Emma Dernoncourt1,2,3,†, Christine Delteil1,2,3, Carine Froment1,2, Odile Schiltz1,2, Bernard Salles1,2, Philippe Frit1,2,3,* and Patrick Calsou1,2,3,* 1CNRS, IPBS (Institut de Pharmacologie et de Biologie Structurale), BP 64182, 205 route de Narbonne, F-31077 Toulouse, Cedex 4, France, 2Universite´ de Toulouse, UPS, IPBS, F-31077 Toulouse, France and 3Equipe Labellisee´ Ligue Nationale Contre le Cancer Received March 11, 2014; Revised June 01, 2014; Accepted June 23, 2014 ABSTRACT INTRODUCTION We previously identified the heterogeneous ribonu- Deoxyribonucleic acid (DNA) double-strand break (DSB) cleoprotein SAF-A/hnRNP U as a substrate for DNA- is the most toxic type of DNA damage. If improperly re- PK, a protein kinase involved in DNA damage re- paired, DSBs can cause cell death or mutations and gross sponse (DDR). Using laser micro-irradiation in hu- chromosomal rearrangements promoting cancer develop- man cells, we report here that SAF-A exhibits a two- ment (1–4). In mammalian cells, DSBs initiate a global DNA damage response (DDR) to overcome their toxicity phase dynamics at sites of DNA damage, with a and maintain genome stability. DDR includes lesions detec- rapid and transient recruitment followed by a pro- tion, checkpoint activation, modulation of gene expression longed exclusion. SAF-A recruitment corresponds to and DNA repair (5–9). DDR defects manifest as a variety its binding to Poly(ADP-ribose) while its exclusion of human diseases, including neurodegenerative disorders, is dependent on the activity of ATM, ATR and DNA- immunodeficiency, infertility and cancer (5).
    [Show full text]
  • Global Patterns of Changes in the Gene Expression Associated with Genesis of Cancer a Dissertation Submitted in Partial Fulfillm
    Global Patterns Of Changes In The Gene Expression Associated With Genesis Of Cancer A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy at George Mason University By Ganiraju Manyam Master of Science IIIT-Hyderabad, 2004 Bachelor of Engineering Bharatiar University, 2002 Director: Dr. Ancha Baranova, Associate Professor Department of Molecular & Microbiology Fall Semester 2009 George Mason University Fairfax, VA Copyright: 2009 Ganiraju Manyam All Rights Reserved ii DEDICATION To my parents Pattabhi Ramanna and Veera Venkata Satyavathi who introduced me to the joy of learning. To friends, family and colleagues who have contributed in work, thought, and support to this project. iii ACKNOWLEDGEMENTS I would like to thank my advisor, Dr. Ancha Baranova, whose tolerance, patience, guidance and encouragement helped me throughout the study. This dissertation would not have been possible without her ever ending support. She is very sincere and generous with her knowledge, availability, compassion, wisdom and feedback. I would also like to thank Dr. Vikas Chandhoke for funding my research generously during my doctoral study at George Mason University. Special thanks go to Dr. Patrick Gillevet, Dr. Alessandro Giuliani, Dr. Maria Stepanova who devoted their time to provide me with their valuable contributions and guidance to formulate this project. Thanks to the faculty of Molecular and Micro Biology (MMB) department, Dr. Jim Willett and Dr. Monique Vanhoek in embedding valuable thoughts to this dissertation by being in my dissertation committee. I would also like to thank the present and previous doctoral program directors, Dr. Daniel Cox and Dr. Geraldine Grant, for facilitating, allowing, and encouraging me to work in this project.
    [Show full text]
  • Clinical Efficacy and Immune Regulation with Peanut Oral
    Clinical efficacy and immune regulation with peanut oral immunotherapy Stacie M. Jones, MD,a Laurent Pons, PhD,b Joseph L. Roberts, MD, PhD,b Amy M. Scurlock, MD,a Tamara T. Perry, MD,a Mike Kulis, PhD,b Wayne G. Shreffler, MD, PhD,c Pamela Steele, CPNP,b Karen A. Henry, RN,a Margaret Adair, MD,b James M. Francis, PhD,d Stephen Durham, MD,d Brian P. Vickery, MD,b Xiaoping Zhong, MD, PhD,b and A. Wesley Burks, MDb Little Rock, Ark, Durham, NC, New York, NY, and London, United Kingdom Background: Oral immunotherapy (OIT) has been thought to noted during OIT resolved spontaneously or with induce clinical desensitization to allergenic foods, but trials antihistamines. By 6 months, titrated skin prick tests and coupling the clinical response and immunologic effects of peanut activation of basophils significantly declined. Peanut-specific OIT have not been reported. IgE decreased by 12 to 18 months, whereas IgG4 increased Objective: The study objective was to investigate the clinical significantly. Serum factors inhibited IgE–peanut complex efficacy and immunologic changes associated with OIT. formation in an IgE-facilitated allergen binding assay. Secretion Methods: Children with peanut allergy underwent an OIT of IL-10, IL-5, IFN-g, and TNF-a from PBMCs increased over protocol including initial day escalation, buildup, and a period of 6 to 12 months. Peanut-specific forkhead box protein maintenance phases, and then oral food challenge. Clinical 3 T cells increased until 12 months and decreased thereafter. In response and immunologic changes were evaluated. addition, T-cell microarrays showed downregulation of genes in Results: Of 29 subjects who completed the protocol, 27 ingested apoptotic pathways.
    [Show full text]
  • Anti-HNRNPUL1 / E1B-AP5 Antibody (ARG42875)
    Product datasheet [email protected] ARG42875 Package: 100 μl anti-HNRNPUL1 / E1B-AP5 antibody Store at: -20°C Summary Product Description Rabbit Polyclonal antibody recognizes HNRNPUL1 / E1B-AP5 Tested Reactivity Hu Tested Application IHC-P, WB Host Rabbit Clonality Polyclonal Isotype IgG Target Name HNRNPUL1 / E1B-AP5 Antigen Species Human Immunogen Synthetic peptide of Human HNRNPUL1 / E1B-AP5. Conjugation Un-conjugated Alternate Names HNRPUL1; E1BAP5; Adenovirus early region 1B-associated protein 5; Heterogeneous nuclear ribonucleoprotein U-like protein 1; E1B-55 kDa-associated protein 5; E1B-AP5 Application Instructions Application table Application Dilution IHC-P 1:50 - 1:200 WB 1:2000 - 1:10000 Application Note * The dilutions indicate recommended starting dilutions and the optimal dilutions or concentrations should be determined by the scientist. Positive Control K562 Calculated Mw 96 kDa Observed Size ~ 95 kDa Properties Form Liquid Purification Affinity purified. Buffer 50 nM Tris-Glycine (pH 7.4), 0.15M NaCl, 0.01% Sodium azide, 40% Glycerol and 0.05% BSA. Preservative 0.01% Sodium azide Stabilizer 40% Glycerol and 0.05% BSA Storage instruction For continuous use, store undiluted antibody at 2-8°C for up to a week. For long-term storage, aliquot and store at -20°C. Storage in frost free freezers is not recommended. Avoid repeated freeze/thaw cycles. Suggest spin the vial prior to opening. The antibody solution should be gently mixed before use. www.arigobio.com 1/2 Note For laboratory research only, not for drug, diagnostic or other use. Bioinformation Gene Symbol HNRNPUL1 Gene Full Name heterogeneous nuclear ribonucleoprotein U-like 1 Background This gene encodes a nuclear RNA-binding protein of the heterogeneous nuclear ribonucleoprotein (hnRNP) family.
    [Show full text]
  • LEF-1 Drives Aberrant Я-Catenin Nuclear Localization in Myeloid
    Acute Myeloid Leukemia SUPPLEMENTARY APPENDIX LEF-1 drives aberrant -catenin nuclear localization in myeloid leukemia cells β Rhys G. Morgan, 1,2 Jenna Ridsdale, 3 Megan Payne, 1 Kate J. Heesom, 4 Marieangela C. Wilson, 4 Andrew Davidson, 1 Alexander Greenhough, 1 Sara Davies, 3 Ann C. Williams, 1 Allison Blair, 1 Marian L. Waterman, 5 Alex Tonks 3 and Richard L. Darley 3 1School of Life Sciences, University of Sussex, Brighton, UK; 2School of Cellular and Molecular Medicine, University of Bristol, UK; 3Depart - ment of Haematology, Division of Cancer and Genetics, School of Medicine, Cardiff University, UK; 4University of Bristol Proteomics Facility, UK and 5Department of Microbiology and Molecular Genetics, University of California, Irvine, CA, USA ©2019 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol. 2018.202846 Received: July 26, 2018. Accepted: January 3, 2019. Pre-published: January 10, 2019. Correspondence: RICHARD DARLEY - [email protected] RHYS MORGAN - [email protected] Morgan et al, 2019 LEF-1 regulates β-catenin nuclear localization Supplementary Table S1. Clinical characteristics of AML/MDS patient diagnostic/relapse samples used in this study. Patient Age (at Sex WBC Sample Secondary Genetic information Other clinical information no. diagnosis) count type disease (x109/L) (Y/N) 1 76 F 389 LP N Normal karyotype, NPM1+, FLT3+ n/a 2 4 M n/a BM n/a n/a n/a 3 10 F n/a BM n/a n/a Deceased 4 n/a n/a >200 PB Y n/a Post-allogeneic transplant. M0/1 (previously diagnosed with M3 10 years previous) 5 6 M n/a BM Y n/a Relapse 6 17 M n/a BM Y n/a Post-BMT for AML following 2 relapses.
    [Show full text]
  • The Regulation of P53 Transcriptional Activity by Hnrnpul-1 and the DNA Damage Response Induced by a Novel
    The regulation of p53 transcriptional activity by hnRNPUL-1 and the DNA damage response induced by a novel chemotherapeutic agent, ALX By Anoushka Thomas A thesis presented to the University of Birmingham, for the degree of Doctor of Philosophy School of Cancer Sciences School of Medical and Dental Sciences University of Birmingham University of Birmingham Research Archive e-theses repository This unpublished thesis/dissertation is copyright of the author and/or third parties. The intellectual property rights of the author or third parties in respect of this work are as defined by The Copyright Designs and Patents Act 1988 or as modified by any successor legislation. Any use made of information contained in this thesis/dissertation must be in accordance with that legislation and must be properly acknowledged. Further distribution or reproduction in any format is prohibited without the permission of the copyright holder. Summary The tumour suppressor, p53, is a vital DNA damage response protein and its means of transcriptional regulation are vast. hnRNPUL-1 is a multifunctional protein and previous studies have implicated it in the modulation of p53 transcriptional activity, although this has been rather poorly understood. Results presented here demonstrate that hnRNPUL-1 represses p53 transcriptional activity and negatively regulates p21 levels. This is consistent with the depletion of hnRNPUL-1 leading to an increase in cells arrested in G1/S. Together these results confirm that hnRNPUL-1 acts as a p53 co-repressor with specific cellular targets. Mutations in p53 and other DNA damage response proteins not only often contribute to the onset of tumourigenesis but can also be the cause of drug resistance during treatment.
    [Show full text]
  • Transcript Length Frequency 0 0 50 0 100 9 200 20 300 33 400 89 500
    Transcript Length Frequency 00 50 0 100 9 200 20 300 33 400 89 500 171 600 231 700 299 800 341 900 465 1000 1,576 1500 2,526 2000 2,786 2500 2,527 3000 2,245 3500 1,741 4000 1,269 4500 1,023 5000 684 >5000 1,408 RefSeq Status Count INFERRED 6 PREDICTED 2480 PROVISIONAL 13796 REVIEWED 183 VALIDATED 2978 19443 Count of Strain Strain Total C57BL/6J 4235 129 71 C57BL/6 4841 102/El 1 Other C57 175 129/J 18 129 substrains 426 129/Ola 21 other 3789 129/Sv 138 unknown 5977 129/SvcJ7 6 19443 129/SvEv 14 129/SvEvTac 1 129/SvEvTacfBr 2 129/SvHe 1 129/SvJ 141 129/SvJ1 1 129/SvPas 1 129S3/SvImJ 1 129S6 1 129S6/SvEvTac 8 129Sv/ImJ 1 3h1 1 A/J 9 A/Sn 2 AKR 8 AKR/J 5 AKXL 1 AQR 1 B10.A 7 B10.BR 1 B10.D1/nSn 1 B10.D2/oSn 3 B10.M 1 B10.MOLunknownSGR 1 B10.RIII 1 B10.WR 2 B6.Kbunknown/unknownDbunknown/unknown 2 B6.S 2 B6/D2 1 B6C3/Fe 1 B6C3F1 2 B6CBAF2 1 B6D2 1 B6D2/J 1 B6D2F1 7 B6D2F1/J 6 B6SJLF1 1 BABunknown14 2 BALB.A2G 1 BALB/c 726 BALB/cAnPtD 1 BALB/cByJ 2 BALB/cCrSlc 1 BALB/cJ 6 BALB/cRl 1 BALB/cRos 1 BC8 1 BDF1 5 BFM/2Msf 1 BJR 1 BXHunknown2 1 C.B17 2 C.B17unknownscid 2 C129 1 C3H 35 C3H/An 11 c3h/e1 1 C3H/He 30 C3H/HeJ 10 C3H/HeN 6 C3H/HeNSIc 1 C3H/J 3 C3HeB/FeJ 2 C3HF 2 C57 8 C57BL 110 C57BL/10 10 C57BL/10J 8 C57BL/10SnJ 1 C57BL/6 4841 C57BL/6CrSlc 1 C57BL/6J 4235 C57BL/6N 15 C57BL/6NCrl 11 C57BL/6Nimr 1 c57bl/6x129/sv 1 C57BL/J 2 C57BL/Ka 1 C57BL/Rij 1 C57BL/WldS 2 C57BL6/Cr 1 C57BLKS 2 CBA 5 CBA/Ca 3 CBA/CaJ 1 CBA/J 4 CBA/N 1 CDunknown1 126 CDunknown1/Hsd 2 CFunknown1 4 CZECHII 349 D0.11.10 1 DAT 1 DBA 4 DBA/2 18 DBA/2Ibg 1 DBA/2J 15 DBA/LiHa
    [Show full text]